Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroma Security Regulatory News (CSSG)

Share Price Information for Croma Security (CSSG)

Share Price is delayed by 15 minutes
Get Live Data
67.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 5.00 (7.692%)
Market Cap: £9.29m
CSSG Live PriceLast checked at - London Stock Exchange

Intraday Croma Security Share Chart

Issue of Equity

16 Nov 2009 18:18

RNS Number : 5997C
Croma Group PLC
16 November 2009
 



Croma Group PLC

Issue of equity and directors' dealings 

The Board of Croma Group PLC ("Croma" or the "Company") announces that, on 16 November 2009, it issued and allotted 6,500,000 new ordinary shares of 0.1 pence each ("New Ordinary Shares") (representing approximately 3.66 per cent. of the current issued share capital of the Company) at a price of 2.0 pence per share (the "Subscription Price"), to directors raising £130,000 (before expenses) pursuant to a subscription. The net subscription proceeds will be used for the repayment of debt. 

The New Ordinary Shares are being subscribed for under existing authorities to issue and allot shares. 

Application has been made to the London Stock Exchange for the 6,500,000 New Ordinary Shares to be admitted to trading on AIM and it is expected that dealings will commence on or around 20 November 2009. 

Directors' dealings 

Pursuant to the subscription, Sebastian Morley, a director of the Company, has subscribed for 2,500,000 New Ordinary Shares at the Subscription Price. Following this transaction, Sebastian Morley's beneficial interest in the Company is 21,028,634 ordinary shares, representing approximately 11.44 per cent. of the enlarged issued share capital of the Company. 

Gerald McGill, a director of the Company, has subscribed for 500,000 New Ordinary Shares at the Subscription Price pursuant to the subscription. Following this transaction, Gerald McGill's beneficial interest in the Company is 1,250,000 ordinary shares, representing approximately 0.68 per cent. of the enlarged issued share capital of the Company. 

James Sullivan, a director of the Company, has subscribed for 1,000,000 New Ordinary Shares at the Subscription Price pursuant to the subscription. Following this transaction, James Sullivan's beneficial interest in the Company is 1,000,000 ordinary shares, representing approximately 0.54 per cent. of the enlarged issued share capital of the Company. 

Furthermore, Nicholas Hewson, a director of the Company, has subscribed for 2,500,000 New Ordinary Shares at the Subscription Price pursuant to the subscription. Following this transaction, Nicholas Hewson's beneficial interest in the Company is 6,354,342 ordinary shares, representing approximately 3.46 per cent. of the enlarged issued share capital of the Company. 

Total Voting Rights

In accordance with FSA's Disclosure and Transparency Rules, the Company advises that its increased issued share capital comprises 183,883,964 ordinary shares of 0.1 pence each. The voting rights of all of these shares are identical with each share carrying the right to one vote. The Company holds no ordinary shares in Treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Croma Group Plc under the Disclosure and Transparency Rules.

For further information contact:

Croma Group PLC:

Sebastian Morley, CEO

Tel: 07768 006909

Brewin Dolphin:

Sandy Fraser, Managing Director - Corporate Finance (NOMAD)

Tel: 0845 213 2072

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEBFBPTMMBBBPL
Date   Source Headline
3rd Jul 20237:00 amRNSCompletion of the Disposal & Total Voting Rights
30th Jun 20239:32 amRNSResult of General Meeting
6th Jun 20237:00 amRNSProposed Disposal of Vigilant for £6.5 million
28th Apr 20237:00 amRNSDirectorate Change
4th Apr 20237:00 amRNSDirectorate Change
14th Mar 20237:00 amRNSHalf-year Report
20th Jan 20237:00 amRNSDirectorate Change
20th Dec 20227:00 amRNSAcquisition of Safecell Security Group
6th Dec 20223:51 pmRNSResult of AGM
6th Dec 20227:00 amRNSAGM Statement, Potential Divestment, Board Changes
11th Nov 20227:00 amRNSFinal Results
27th Oct 20227:00 amRNSPublication of 2022 Final Results
15th Sep 20227:00 amRNSContract Wins & Trading Update
6th Jul 20227:00 amRNSAcquisition
31st Mar 20225:08 pmRNSDirector/PDMR Shareholding
29th Mar 20222:50 pmRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSHalf-year Report
24th Jan 20227:00 amRNSStrategic Partnership
26th Nov 202112:03 pmRNSGrant of Options, PDMR dealing
24th Nov 20211:36 pmRNSResult of AGM
18th Nov 20217:00 amRNSAcquisition
8th Nov 202112:28 pmRNSHolding(s) in Company
28th Oct 20212:38 pmRNSHolding(s) in Company
21st Oct 20217:00 amRNSFinal Results
6th Oct 202110:54 amRNSHolding(s) in Company
4th Oct 20217:00 amRNSTrading Statement and Strategic Partnership
2nd Jul 20217:44 amRNSHolding(s) in Company
28th Jun 20217:00 amRNSTrading Statement
24th Mar 20217:00 amRNSDirector/PDMR Shareholding
12th Mar 202110:07 amRNSHolding(s) in Company
1st Mar 20217:00 amRNSHalf-year Report
18th Jan 20217:00 amRNSHolding(s) in Company
25th Nov 20201:52 pmRNSResult of AGM
21st Oct 20207:00 amRNSFinal Results
13th Aug 202011:00 amRNSDividend Reinstated and Contract Win
2nd Jul 20207:00 amRNSDirector/PDMR Shareholding
1st Jul 20207:00 amRNSDirector/PDMR Shareholding
15th Jun 20207:00 amRNSContract Renewal and Uplift
8th Jun 20207:00 amRNSTrading Update
4th Jun 20204:40 pmRNSSecond Price Monitoring Extn
4th Jun 20204:35 pmRNSPrice Monitoring Extension
19th Mar 20203:01 pmRNSCancellation of Dividend
2nd Mar 20207:00 amRNSHalf-year Report
4th Feb 20208:12 amRNSHolding(s) in Company
24th Jan 202012:00 pmRNSHolding(s) in Company
27th Nov 20191:32 pmRNSResult of AGM
21st Oct 20197:00 amRNSFinal Results
29th Mar 20196:00 pmRNSHolding(s) in Company
18th Mar 201912:58 pmRNSDirector/PDMR Shareholding
26th Feb 20194:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.